Frequently Asked Questions
Why is an Ozempic compliance program necessary?
Healthcare is a highly regulated industry, and an effective compliance program helps to reduce the risk of regulatory noncompliance.
What are the elements of an Ozempic compliance program?
Compliance programs typically include seven elements, including written policies and procedures; employee training and education; monitoring; and remedial action.
Who is responsible for administering an Ozempic compliance program?
Depending on the size of the business, compliance oversight may be performed by a designed Chief Compliance Officer, Compliance Committee, or Board of Directors. In smaller businesses, a Compliance Manager or Business Lead may perform the function.
In September 2025, the Food and Drug Administration issued over 50 Warning Letters to companies for marketing compounded GLP’s as ‘generic versions’ or that make comparative claims to FDA-approved versions. This has long been the focus of Cease & Desist letters from the brand manufacturers to 503A compounders. FDA also issued a series of letters regarding mostly peptides being sold as ‘research use only’ (RUO) where the advertising indicated the product was intended for human use. The Warning Letters targeted mostly semaglutide, tirzepatide and retatrutide as well as other peptides such as BPC-157 and selective androgen receptor or anabolic steroids (SARMS) such as trendione. Retatrutide cannot be compounded at all because it is an investigational drug. Other Warning Letters pertained to insanitary conditions for 503A compounders. FDA inspects 503A compounders pursuant to its insanitary guidance standards rather than USP and compounders need to be fluent in the requirements of that Guidance.
In September 2025, the Food and Drug Administration issued over 50 Warning Letters to companies for marketing compounded GLP’s as ‘generic versions’ or that make comparative claims to FDA-approved versions.
Warning Letters issued to 503B Outsourcing Facilities were for cGMP violations, failure to submit Adverse Drug Reaction (ADR) reports to FDA (which 503B facilities are required to report), compounding unapproved drug products. Some 503B Warning letters involved mislabeling where the compounded product did not bear the label ‘this is a compounded drug’ or ‘this is a repackaged drug.’ Others pertained to inadequate Policies & Procedures (P&P) for the Quality Control units.
Also in September 2025, FDA established a ‘Green List Import Alert’ (66-80) to help stop GLP-1 API’s that have potential quality concerns from entering the U.S. supply chain. Concurrently, FDA has increased unannounced inspections of foreign API manufacturers and is also stepping up Remote Inspections via FDA form 4003.
FDA has increased unannounced inspections of foreign API manufacturers and is also stepping up Remote Inspections via FDA form 4003.
Whether you are a 503A pharmacy compounder or a 503B Outsourcing Facility you should have your labeling, Website and Social Media advertising, P&P and compounded products reviewed for compliance with current FDA Guidance. If you are facing either an FDA or Board of Pharmacy inspection or just need to get up to speed on the latest compounding requirements, contact us today.
MORE ARTICLES BY CATEGORY
California Hospice Fraud Crackdown: What it Means for Providers & How to Protect Your Business
California’s hospice fraud crackdown is only the beginning of what CMS and Medi-Cal regulators have claimed will be many more cases brought against hospice facilities and home health agencies. Providers who do not timely respond to a suspension or revocation may waive important rights. Act now to protect your business and reputation from governmental overreach based on data mining and other unreliable sources.
Read More >>The WISeR Model: A New Era of Prior Authorization and Audit Risks for Wound Care
On January 1, 2026, the Centers for Medicare & Medicaid Services (CMS) officially launched the Wasteful and Inappropriate Service Reduction (WISeR) Model. This initiative is not just another administrative hurdle; it is a technology-driven enforcement overhaul aimed directly at the wound care industry.
Read More >>OMIG Audit Defense New York: What the 2026 Work Plan Means for Providers
Every year, the New York Office of the Medicaid Inspector General (OMIG) releases its Work Plan outlining enforcement priorities. The 2026 plan sends a clear signal that Medicaid providers in New York are entering a far more aggressive enforcement environment.
Read More >>PBM Member Denial Audit Findings: A Growing Threat to Pharmacies
Pharmacies undergoing a Pharmacy Benefit Manager (PBM) audit are typically prepared to address inventory discrepancies and documentation issues. What many are not prepared for, however, is the increasing use of PBM member denial findings, allegations that a patient claims they did not receive and/or did not authorize the dispensing of a medication for which a claim was submitted.
Read More >>